# Clinical-trial insurance brokerage Specialist insurance brokers who structure and place subject-injury, professional-indemnity and product-liability coverage for a clinical trial program, harmonizing the statutorily-required local insurance of every country a trial runs in into a single manageable placement. Source: https://en.bioecon.ru/technology/clinical-trial-insurance-brokerage/ Updated: 2026-08-18 ## Overview and value chain Markers: [EC: Structuring and placing clinical-trial subject-injury and liability insurance across trial jurisdictions | OECD: Biopharmaceutical clinical development | Regulator: FDA (US), EMA (EU)] Clinical-trial insurance brokerage places the coverage a sponsor is legally required to carry — or contractually obligated to provide a site under a Clinical Trial Agreement — before a study can enroll its first subject. Newline Group, a Lloyd's-market underwriting manager based in London, runs a dedicated Clinical Trials product line offering life-of-trial policies of up to ten years' duration, country-specific annual "all trial" policies, and bespoke multi-country or global master difference-in-conditions/difference-in-limits programs. Marsh, one of the world's largest insurance brokers, is named among the leading placement houses for clinical-trial coverage by independent market comparisons. Howden, a UK-headquartered global broker, published a 2026 sector report on how insurance can support the UK pharma industry through its current transition, reflecting its active life-sciences practice. Gallagher's Life Sciences practice published a dedicated whitepaper, "Mitigating Risks Through Clinical Trial Funding Insurance," alongside a Winter 2026 market summary specifically covering pharmaceutical, biotechnology, medical-device, CRO and CMO clients. WTW (Willis Towers Watson) publishes ongoing analysis of clinical-trial insurance underwriting trends, including the growing role of trial medical-expense coverage and 2025 rate predictions for life-sciences products and professional liability. The key directions of clinical-trial insurance brokerage are: 1. **Subject-injury and liability placement:** structuring coverage for bodily injury and medical expenses incurred by trial participants, alongside sponsor and site professional-indemnity and product-liability exposure. 2. **Multi-jurisdiction program harmonization:** placing a single master or difference-in-conditions/difference-in-limits policy that satisfies the differing statutory clinical-trial insurance requirements of every country a study runs in. 3. **Life-of-trial and annual policy structuring:** choosing between a single policy covering a trial's full multi-year duration versus renewable annual "all trial" country-specific policies, depending on program length and portfolio size. 4. **Site indemnification advisory:** advising sponsors and research sites on the insurance and indemnification terms of the Clinical Trial Agreement or Master Services Agreement before a site signs on. ### Sectoral value chain ``` [Trial protocol & jurisdiction scoping] ──> [Coverage structuring & underwriter placement] ──> [Policy issuance across trial countries] │ (Site indemnification review) │ [Claims handling to closure] <──── [Ongoing program renewal/amendment] <─── [Subject-injury claim intake] ``` ### Value chain levels | Level | Description | Key inputs/outputs | |:---|:---|:---| | **Protocol & jurisdiction scoping** | Reviewing the trial protocol and the list of countries/sites it will run in to determine the statutory insurance requirements that apply. | **In:** Trial protocol, site/country list.
**Out:** Jurisdictional coverage requirement matrix. | | **Coverage structuring & placement** | Structuring the policy (life-of-trial vs. annual, master vs. local) and placing it with underwriters. | **In:** Jurisdictional coverage requirement matrix.
**Out:** Placed insurance program. | | **Policy issuance across trial countries** | Issuing the local policy documentation required in each jurisdiction under the master program. | **In:** Placed insurance program.
**Out:** Country-specific policy documents. | | **Site indemnification review** | Advising sponsor and site on the Clinical Trial Agreement's insurance and indemnification terms before signing. | **In:** Country-specific policy documents, draft CTA/MSA.
**Out:** Reviewed indemnification terms. | | **Subject-injury claim intake** | Receiving and triaging a reported subject-injury or liability event during trial conduct. | **In:** Reported adverse/injury event.
**Out:** Intake claim file. | | **Claims handling to closure** | Managing the claim through investigation, negotiation and settlement or denial, and feeding lessons into program renewal. | **In:** Intake claim file.
**Out:** Closed claim, renewal/amendment input. | Cross-cutting technologies of the sector: - **Clinical-trial liability placement:** specialist insurance-broking practice that structures and places subject-injury, professional-indemnity and product-liability coverage for a specific clinical trial program across the jurisdictions it runs in. - **Multi-country trial insurance programs:** master or difference-in-conditions/difference-in-limits insurance policies that harmonize local, statutorily-required clinical-trial coverage across every country a sponsor's trial operates in under one program. --- ## US The United States hosts two of the largest global insurance-broking houses with dedicated life-sciences practices covering clinical-trial placement. ### Marsh's placement scale, Gallagher's dedicated Life Sciences whitepaper - **Marsh:** named among the leading clinical-trial insurance placement brokers in independent market comparisons, leveraging its position as one of the world's largest insurance brokers to place complex, cross-border trial programs. - **Gallagher:** its Life Sciences practice publishes dedicated clinical-trial funding insurance guidance and a recurring life-sciences insurance market summary covering pharmaceutical, biotech, medical-device, CRO and CMO clients specifically. --- ## CN China is covered qualitatively rather than by a live-screened Chinese vendor: candidate Chinese clinical-trial insurance brokers searched during this screen returned no confirming 2026 source, so no Chinese company is tabled below. Multinational sponsors running trials in China typically place local statutorily-required coverage through the same global brokers' China offices or local co-insurance partners, rather than through a distinct domestic clinical-trial-insurance specialist confirmed on this screen. ### No confirmed domestic specialist; global brokers' China offices place local statutory coverage - **Global broker China offices:** multinational sponsors running China trial sites typically route the locally-required clinical-trial insurance placement through the same global brokers' China operations rather than a distinct domestic specialist. - **Domestic gap:** no China-headquartered clinical-trial insurance brokerage confirmed by a live 2026 source was found during this screen. --- ## EU The European Union — via UK-headquartered brokers and Lloyd's-market underwriters — hosts the deepest specialist clinical-trial insurance capacity, including the sector's dedicated Lloyd's product line. ### Newline's dedicated Lloyd's product line, Howden's UK life-sciences transition report, WTW's underwriting-trend analysis - **Newline Group:** a Lloyd's-market underwriting manager running a dedicated Clinical Trials product line — life-of-trial policies up to ten years, country-specific annual "all trial" policies, and bespoke multi-country or global master difference-in-conditions/difference-in-limits programs. - **Howden:** published a 2026 report on how insurance can support the UK pharmaceutical and life-sciences sector through its current transition, reflecting an active dedicated life-sciences broking practice. - **WTW (Willis Towers Watson):** publishes ongoing analysis of clinical-trial insurance underwriting trends, including trial medical-expense coverage evolution and life-sciences product/professional-liability rate predictions. --- ## Leading companies and research institutes | Company / Institute | Country | Key products / platforms | Tech features | Status 2026 | |:---|:---|:---|:---|:---| | **Newline Group** | 🇬🇧 UK | Dedicated Clinical Trials product line (Lloyd's) | Life-of-trial policies to 10 years, multi-country DIC/DIL | commercial | | **Marsh** | 🇺🇸 USA | Clinical-trial insurance placement | Leading global placement scale | commercial | | **Howden** | 🇬🇧 UK | Life-sciences insurance broking | UK pharma-sector transition advisory | commercial | | **Gallagher** | 🇺🇸 USA | Life Sciences practice, clinical-trial funding insurance | Dedicated whitepaper + market-summary research | commercial | | **WTW** | 🇬🇧 UK | Clinical-trial insurance underwriting analysis | Trial medical-expense coverage evolution tracking | commercial | --- ## Tech stack and innovations The clinical-trial insurance brokerage "technology stack" is less software than structuring know-how, applied through a small set of recurring policy mechanisms: 1. **Difference-in-conditions/difference-in-limits (DIC/DIL) master programs:** - Newline's global master programs harmonize varying local statutory minimums into one placement, avoiding a patchwork of separately negotiated local policies. 2. **Life-of-trial vs. annual policy structuring:** - Brokers choose between a single policy spanning a trial's full multi-year duration and renewable annual all-trial policies, trading premium certainty against flexibility as a program's country footprint changes. 3. **Sector-specific market-trend research feeding placement strategy:** - Gallagher and WTW both publish recurring life-sciences insurance market analysis that directly informs how a given trial program is structured and timed for placement. --- ## Value chains and production pipelines ### Industrial pipeline for clinical-trial insurance placement ``` ┌───────────────────────────┐ ┌───────────────────────────┐ │ 1. Protocol & jurisdiction │ ───> │ 2. Coverage structuring & │ │ scoping │ │ underwriter placement │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 4. Site indemnification │ <─── │ 3. Policy issuance across │ │ review │ │ trial countries │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 5. Subject-injury claim │ ───> │ 6. Claims handling to │ │ intake │ │ closure │ └───────────────────────────┘ └───────────────────────────┘ ``` #### Stage 1: Protocol and jurisdiction scoping The broker reviews the trial protocol and the list of countries and sites it will run in to determine which statutory clinical-trial insurance requirements apply. #### Stage 2: Coverage structuring and underwriter placement The broker structures the policy — life-of-trial or annual, master program or local — and places it with one or more underwriters, often via the Lloyd's market for specialist life-sciences risk. #### Stage 3: Policy issuance across trial countries Local policy documentation required in each jurisdiction is issued under the umbrella of the master program. #### Stage 4: Site indemnification review The broker or sponsor's risk team reviews the Clinical Trial Agreement or Master Services Agreement's insurance and indemnification terms before a site signs. #### Stage 5: Subject-injury claim intake A reported subject-injury or liability event during trial conduct is received and triaged into a claim file. #### Stage 6: Claims handling to closure The claim is investigated, negotiated and settled or denied, with lessons feeding back into the next program renewal or amendment.